AcelRx Pharmaceuticals Inc


Stock Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Provides Corporate Update and Announces 3Q and Nine Months 2016 Financial Results

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) provided a business update and reported financial results for the three and nine months ended September 30, 2016. Corporate Highlights …

Company Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Presenting ARX-04 Clinical Trial Findings and Cost Analysis at ECEM

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced that the Company and investigators will be presenting two e-posters at the European Congress on Emergency Medicine (ECEM), …

Stock Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Initiates Phase 3 Study of Zalviso® in Patients with Moderate-to-Severe Acute Post-Operative Pain

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced the initiation of the Phase 3 IAP312 study of Zalviso® (sufentanil sublingual tablet system), an investigational product candidate being …

Stock Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Announces Data Presentation for ARX-04 at Plastic Surgery Meeting

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced that Dr. Shankar Lakshman, a board-certified plastic surgeon and AcelRx clinical investigator, will present a subgroup analysis from …

H.C. Wainwright Bullish on AcelRx Pharmaceuticals Inc (ACRX) Following Positive Phase 3 Trial Results

AcelRx Pharmaceuticals Inc’s (NASDAQ:ACRX) just announced positive top-line results from its third, final Phase 3 trial of pipeline drug ARX-04 designed to treat …

Company Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc to Announce Topline Results in Phase 3 Study of ARX-04 in Patients with Post-Operative Moderate-to-Severe Acute Pain

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) will announce the results of its multicenter, open-label Phase 3 clinical study of ARX-04, known as SAP303. The study …

Stock Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Presents Results from Phase 3 Study of ARX‑04 in the Emergency Department at the International Society for Burn Injuries

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced that the Company and its investigators will be presenting results from the Phase 3 SAP302 study of ARX-04 (sufentanil …

Company Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Completes Patient Enrollment in Remaining Phase 3 Studies of ARX-04 as a Potential Treatment of Moderate-to-Severe Acute Pain

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, …

Stock Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Joins Russell 3000 and Russell 2000 Indexes

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today …

Thursday Morning’s Market Insights: Abercrombie and Fitch Co. (ANF), OvaScience Inc (OVAS), Flexicon Therapeutics Inc (FLXN), AcelRx Pharmaceuticals Inc (ACRX)

Abercrombie & Fitch Co. (NYSE:ANF) is down close to 12% in pre-market trading after the firm released disappointing 1Q:16 earnings this morning.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts